Turnstone Biologics Corp.
TSBX
$0.35
$0.0319.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 0.00 | 19.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 19.31M |
| Cost of Revenue | 39.89M | 42.46M | 42.21M | 42.07M | 41.33M |
| Gross Profit | -39.89M | -42.46M | -42.21M | -42.07M | -22.03M |
| SG&A Expenses | 16.39M | 17.57M | 18.38M | 18.72M | 17.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.37M | 77.11M | 77.68M | 77.47M | 75.86M |
| Operating Income | -73.37M | -77.11M | -77.68M | -77.47M | -56.56M |
| Income Before Tax | -70.80M | -75.38M | -74.88M | -75.09M | -55.49M |
| Income Tax Expenses | 37.00K | -963.00K | -180.00K | -188.00K | -286.00K |
| Earnings from Continuing Operations | -70.84 | -74.42 | -74.70 | -74.90 | -55.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.84M | -74.42M | -74.70M | -74.90M | -55.20M |
| EBIT | -73.37M | -77.11M | -77.68M | -77.47M | -56.56M |
| EBITDA | -71.53M | -74.96M | -75.31M | -74.87M | -53.76M |
| EPS Basic | -3.08 | -3.23 | -3.49 | -10.12 | -14.40 |
| Normalized Basic EPS | -1.94 | -2.00 | -2.14 | -6.28 | -5.61 |
| EPS Diluted | -3.08 | -3.23 | -3.49 | -10.12 | -14.40 |
| Normalized Diluted EPS | -1.94 | -2.00 | -2.14 | -6.28 | -5.61 |
| Average Basic Shares Outstanding | 92.15M | 92.02M | 86.38M | 66.19M | 45.97M |
| Average Diluted Shares Outstanding | 92.15M | 92.02M | 86.38M | 66.19M | 45.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |